# REACH-2 (NCT02435433)

> A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02435433
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Eli Lilly and Company
- Conditions: Hepatocellular Carcinoma
- Interventions: Ramucirumab; Placebo
- Enrollment: 399
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 16
- YouTube: 11
- X threads: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=reach-2-nct02435433

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02435433", "email": "<work email>"}; the inbox owner confirms by the emailed link.